Tetrabenazine

What is Tetrabenazine?

Tetrabenazine is a medication primarily used to treat hyperkinetic movement disorders. It is a central nervous system depressant that helps manage involuntary movements. Specifically, it is approved for the treatment of chorea associated with Huntington's disease and for tardive dyskinesia. As a unique agent in its class, Tetrabenazine works by affecting certain neurotransmitters in the brain, thereby reducing the severity and frequency of uncontrolled movements. It is not a cure for the underlying conditions but rather a symptomatic treatment that can significantly improve a patient's quality of life by mitigating debilitating motor symptoms.

How Does it Work?

The mechanism of action of Tetrabenazine primarily involves its role as a VMAT2 inhibitor (Vesicular Monoamine Transporter Type 2 inhibitor). VMAT2 is a protein responsible for packaging monoamines (such as dopamine, serotonin, and norepinephrine) into synaptic vesicles within nerve terminals. By reversibly inhibiting VMAT2, Tetrabenazine prevents these neurotransmitters from being adequately stored and subsequently released into the synaptic cleft. This leads to a reduction in the presynaptic stores of monoamines, particularly dopamine, in the brain. The resulting decrease in dopaminergic activity in certain brain regions, especially the basal ganglia, is believed to be responsible for its therapeutic effects in reducing involuntary movements. This targeted monoamine depletion helps to rebalance neurotransmitter levels, thereby calming the excessive neural activity that causes conditions like chorea and dyskinesia.

Medical Uses

Chorea Associated with Huntington's Disease

The primary approved indication for Tetrabenazine is the symptomatic treatment of chorea associated with Huntington's disease. Chorea is a neurological disorder characterized by involuntary, irregular, unpredictable muscle movements. These movements can affect various parts of the body, including the face, trunk, and limbs, and can severely impair daily activities. Tetrabenazine helps to reduce the frequency and severity of these choreic movements, offering significant relief to patients.

Tardive Dyskinesia

Tetrabenazine is also approved for the treatment of tardive dyskinesia. This condition is characterized by involuntary, repetitive movements, often affecting the face (e.g., grimacing, tongue protrusion, lip smacking) and limbs. Tardive dyskinesia is typically a side effect of long-term use of dopamine receptor blocking agents, such as antipsychotic medications. By modulating dopamine levels, Tetrabenazine can help alleviate these distressing and often socially isolating movements.

Dosage

The dosage of Tetrabenazine must be carefully individualized and titrated by a healthcare professional. Treatment typically begins with a low dose, which is then gradually increased over several weeks based on the patient's response and tolerability. This titration process is crucial to find the optimal therapeutic dose while minimizing side effects. Tetrabenazine is usually taken orally, two to three times a day, and should generally be administered with food to enhance absorption and reduce gastrointestinal upset. It is important never to adjust the dosage or discontinue the medication without consulting a doctor, as abrupt cessation can lead to withdrawal symptoms or a worsening of movement disorders.

Side Effects

Like all medications, Tetrabenazine can cause side effects. Common side effects include:

• Sedation or drowsiness
• Fatigue
• Nausea or vomiting
• Insomnia
• Depression or mood changes
• Parkinsonism (e.g., tremor, rigidity, bradykinesia)
• Anxiety
• Dizziness

More serious, though less common, side effects can include:

• Neuroleptic Malignant Syndrome (NMS): A rare but severe reaction characterized by high fever, muscle rigidity, altered mental status, and autonomic dysfunction.
• Depression with suicidal ideation: Patients, especially those with a history of depression, should be closely monitored.
• QT prolongation: Although rare, this can lead to serious heart rhythm abnormalities.

Patients should report any new or worsening side effects to their doctor promptly. It is crucial to discuss all existing medical conditions and medications with a healthcare provider before starting Tetrabenazine.

Drug Interactions

Tetrabenazine can interact with several other medications, potentially altering its effects or increasing the risk of adverse reactions. Important drug interactions include:

• Monoamine Oxidase Inhibitors (MAOIs): Concomitant use with MAOIs is contraindicated due to the risk of hypertensive crisis. A washout period is required between stopping an MAOI and starting Tetrabenazine.
• CYP2D6 Inhibitors: Tetrabenazine is metabolized by the enzyme CYP2D6. Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) can increase Tetrabenazine levels, necessitating a dose adjustment.
• Drugs that Prolong QT Interval: Concurrent use with other medications known to prolong the QT interval can increase the risk of cardiac arrhythmias.
• CNS Depressants: Alcohol and other CNS depressants (e.g., benzodiazepines, opioids) can exacerbate the sedative effects of Tetrabenazine.
• Reserpine: Should not be used with Tetrabenazine due to additive effects on monoamine depletion.

Always inform your healthcare provider about all prescription, over-the-counter, and herbal supplements you are taking to prevent potential drug interactions.

FAQ

Is Tetrabenazine a cure for Huntington's disease or tardive dyskinesia?

No, Tetrabenazine is not a cure for either condition. It is a symptomatic treatment that helps manage and reduce the severity of involuntary movements associated with these disorders.

How long does it take for Tetrabenazine to work?

The effects of Tetrabenazine are typically not immediate. Dosage titration often takes several weeks, and patients may experience gradual improvement in their symptoms over this period as the optimal dose is reached.

Can I stop taking Tetrabenazine suddenly?

No, Tetrabenazine should not be stopped suddenly. Abrupt discontinuation can lead to a rapid worsening of movement disorders, and in some cases, symptoms resembling Neuroleptic Malignant Syndrome. Any changes to the dosage or discontinuation should be done under the strict guidance of a healthcare professional.

What is VMAT2?

VMAT2 stands for Vesicular Monoamine Transporter Type 2. It is a protein responsible for transporting monoamine neurotransmitters (like dopamine, serotonin, and norepinephrine) from the cytoplasm into synaptic vesicles for storage and subsequent release.

Products containing Tetrabenazine are available through trusted online pharmacies. You can browse Tetrabenazine-based medications at ShipperVIP or Medicenter.

Summary

Tetrabenazine is a crucial medication for individuals suffering from severe hyperkinetic movement disorders such as chorea associated with Huntington's disease and tardive dyskinesia. By acting as a VMAT2 inhibitor, it helps to reduce excessive involuntary movements by modulating monoamine neurotransmitter levels in the brain. While it offers significant symptomatic relief, it requires careful dosage titration and monitoring due to its potential side effects and drug interactions. Patients considering or undergoing treatment with Tetrabenazine should maintain open communication with their healthcare providers to ensure safe and effective management of their condition.